Institutional Investors

SanaCurrents subscribers receive a featured catalyst report every weekend, excluding four holidays.* The report is based on a score from a set of objective data points that establish the probability a biotech catalyst, such as a clinical trial result, will be positive. In our experience, a positive result typically increases the company’s share price. Historical results of SanaCurrents catalyst forecasts are displayed in the charts below.

Institutional subscribers receive featured catalyst reports with a MACE score. MACE stands for Market Demand, Adoption by physicians and key opinion leaders (KOLs), Clinical progress and Experience and capital. The four components of MACE are combined to provide an overall probability score for the catalyst. See an example here.

SanaCurrents typically has 12-20 pending catalysts at any time during the year. Institutional subscribers gain immediate access to all pending catalysts, creating the opportunity to build gains quickly. Institutional subscribers also gain access to four years of SanaCurrents reports.

Also include in the subscription are periodic On the Horizon catalyst forecasts. These catalysts generally have a 45% to 55% probability score because supporting data is very early and/or inconsistent. The market response, however, to even modest clinical progress could trigger a significant increase in the stock price. Examples would include treatments to stop the spread of Sars-CoV-2, or a new approach in Alzheimer’s disease.

Custom catalyst reports are available to institutional subscribers upon request.

*Holidays: Easter, July 4, US Thanksgiving and Christmas